Clinical trials: Moderate COVID-19-infection
COVID-19
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of STI-1558 in adult subjects with mild/moderate COVID-19.
- Trial name
- NCT05716425
- Testing
- STI-1558
- Where
- 2 sites in China
- Volunteers
- 1,218 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Covid19
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
This is an adaptive, Phase I/II study in 2 parts: Part 1 is to evaluate the Maximum Tolerable Dose (MTD) , tolerance, safety and pharmacokinetics of FB2001 in healthy subjects; Part 2 is to evaluate the safety, pharmacokinetics…
- Trial name
- NCT04766931
- Testing
- FB2001
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.
- Trial name
- NCT04475107
- Testing
- Pyronaridine-Artesunate
- Where
- 13 sites in South Korea
- Volunteers
- 113 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
COVID-19
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19 patients.
- Trial name
- NCT05084911
- Testing
- Pyramax
- Where
- 66 sites in Argentina, Chile and 4 more
- Volunteers
- 1,807 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19.
- Trial name
- NCT05212662
- Testing
- TTI-0102
- Sponsor
- Thiogenesis Therapeutics, Inc.
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Covid19
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens.
- Trial name
- NCT04780685
- Testing
- hMSC
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Stemedica Cell Technologies, Inc.
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19 Pneumonia
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe…
- Trial name
- MARIPOSA (NCT04363736)
- Testing
- Tociliuzumab
- Where
- 24 sites in United States
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
- Trial name
- CCBCRISIS04 (NCT05166876)
- Testing
- Brequinar Sodium, Dipyridamole 75 MG
- Where
- 7 sites in India
- Volunteers
- 26 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.
- Trial name
- NCT04329572
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- Azidus Brasil
COVID-19
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
- Trial name
- NCT04292730
- Testing
- Remdesivir, Standard of Care
- Where
- 184 sites in United States, China and 13 more
- Volunteers
- 1,113 people
- Sponsor
- Gilead Sciences
COVID 19 Disease
Tafenoquine in Patients With Mild to Moderate COVID-19
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
- Trial name
- NCT04533347
- Testing
- Tafenoquine Oral Tablet
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC
COVID-19
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of DXP604 in patients with mild to moderate COVID-19.
- Trial name
- NCT05381519
- Testing
- DXP604
- Volunteers
- 50 people
- Sponsor
- Wuhan Institute of Biological Products Co., Ltd
Respiratory Distress Syndrome, Adult
A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
A Phase 1 study of agenT-797 to treat moderate to severe acute respiratory syndrome in Coronavirus disease 2019 (COVID-19) participants.
- Trial name
- NCT04582201
- Testing
- agenT-797
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- MiNK Therapeutics
Hepatic Impairment
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted…
- Trial name
- NCT05005312
- Testing
- PF-07321332, Ritonavir
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in…
- Trial name
- NCT07664696
- Testing
- IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- Volunteers
- 64 people
- Sponsor
- Kimera Labs Inc.
COVID-19 Pneumonia
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.
- Trial name
- NCT05656443
- Testing
- GST-HG171/Ritonavir
- Where
- China
- Volunteers
- 1,246 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
COVID
Niclosamide In Moderate COVID-19
This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.
- Trial name
- NCT04436458
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
COVID-19
MP1032 Treatment in Patients With Moderate to Severe COVID-19
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04932941
- Testing
- MP1032
- Where
- 31 sites in United States, Bulgaria and 5 more
- Volunteers
- 132 people
- Sponsor
- MetrioPharm AG